The mouse is the model of choice for recapitulating genetic changes that give rise to human disease. Over the past 30 years, mouse molecular genetics has been refined to allow production of an impressive range of mutants. These include additive transgenic, knockout mice and knock-in mice (all of which can have conditional mutations or inducible mutations), strains containing chromosomal rearrangements or megabase-sized deletions and duplications and even transchromosomic mouse strains 1 . It is a fast developing area: new technologies are arising all of the time, and they include methods for modelling 'sporadic' disease, such as cancer 2 . Almost all human disease models have been made to study changes in the coding genome. Typically, this has been done by pronuclear injection to generate transgenics that ectopically express a mutant protein or by gene targeting in embryonic stem cells (ESCs): for example, by creating a gene knock-in. As proteins with a human amino acid sequence can have different biochemical characteristics from their mouse orthologues, transgenics have often been made with human cDNAs, and targeting has involved placing human coding sequences into the orthologous mouse gene. This genetic 'humanizing' strategy using coding sequences can result in a more accurate mouse model of disease than working with a mutant mouse protein.
However, recent progress in genomic analysis has highlighted the importance of the non-coding genome (both transcribed and non-transcribed), making it clear that this category of sequence also needs to be taken into account when modelling disease. In particular, projects such as the ENCylopedia Of DNA Elements (ENCODE) 3 have discovered extensive transcription of the non-coding genome, and human genome-wide association studies (GWASs) demonstrate that variation (including copy number variation) in noncoding regions confers susceptibility and resistance to disease in ways that we do not comprehend. As we learn more about the complexity of the genome, it is apparent that understanding human biology, particularly with respect to disease models, will require humanized mouse models that address the potential roles of both coding and non-coding genomic sequence
.
Laboratories worldwide are developing the technology for creating such 'genomically' humanized mice, which are generated by transferring entire human genomic loci (including coding and non-coding regions) into the mouse genome. This is achieved either by the addition of human genomic sequences or by replacing regions of the mouse genome with equivalent human genomic sequences. However, the technical challenges remain daunting, and although current approaches for optimizing different strategies are proving successful, they are far from routine.
Here we look at the different approaches that have been developed for creating genomically humanized mice, why genomic humanization remains a challenge and which new technologies are the most promising. We also speculate on the direction of future advances in this field.
YAC and BAC transgenics
The first technologies for producing genomically humanized mice made use of yeast artificial chromosomes (YACs) and bacterial artificial chromosomes (BACs).
Transgenic lines can be created by pronuclear injection of YAC and BAC DNAs, and these DNAs will integrate at random chromosomal positions (FIG. 1a) . The key advantage of BACs and YACs is their size, ranging up to 300 kilobases (kb) for BACs and up to megabases (Mb) for YACs, thus enabling inclusion of all or some of the upstream and downstream cis-sequences regulating expression of a gene of interest. YAC and BAC transgenic insertions show positionindependent and copy-number-dependent expression more frequently than smaller transgenes do, and they more faithfully recapitulate the anticipated expression profile 4, 5 . Compared with conventional cDNA transgenics, BAC and YAC transgenics also have the advantage of containing low copy number integrations, which is important when studying the effect of gene dosage.
The extent of humanization that is achievable with YACs can be increased by exploiting homologous recombination in yeast to join two existing YACs via a region of shared homology into a single larger recombinant YAC. The recombinant YAC can then be transferred into ESCs by fusion with yeast spheroplasts carrying the YAC, followed by selection for a drug-resistance selection marker (FIG. 1a) . ESCs can then be used to generate chimaeras to achieve germline transmission. Transgenic mice containing the entire functional human TCRαβ-encoding gene loci (encoding the T cell receptor α-and β-chains) were created in this way 6 . BACs can also be manipulated by homologous recombination in Escherichia coli: for example, to insert reporter genes 7 . Genomically humanized YAC and BAC transgenic strains may be bred onto a null background for the gene of interest, such that the humanized locus is the only version of the gene that is expressed 8 (FIG. 1a) . Production of transgenic mice expressing only human antibodies has been achieved by breeding transgenic lines into strains containing knockout alleles of heavy-and light-chain-constant regions (for example, see REF. 9 ).
BACs can also be designed to integrate at specific and ubiquitously expressed chromosomal loci, such as the hypoxanthine guanine phosphoribosyltransferase (Hprt) locus, by homologous recombination 10 or by site-specific recombination (SSR) 11 in ESCs. Site-specific integration avoids the problems due to deletions and concatemerization that can occur during random integration by non-homologous recombination and, as the site of integration is predetermined, it also achieves a more reproducible expression profile.
Genomically humanized mice: technologies and promises
Abstract | Mouse models have become an invaluable tool for understanding human health and disease owing to our ability to manipulate the mouse genome exquisitely. Recent progress in genomic analysis has led to an increase in the number and type of disease-causing mutations detected and has also highlighted the importance of non-coding regions. As a result, there is increasing interest in creating 'genomically' humanized mouse models, in which entire human genomic loci are transferred into the mouse genome. The technical challenges towards achieving this aim are large but are starting to be tackled with success.
Targeted genomic replacement Targeted integration of a human sequence into the equivalent region of the mouse genome in ESCs is the most precise method of humanization, enabling a single copy of human sequence to reside at a natural site for its expression while simultaneously replacing the corresponding mouse sequence. In principle, it is possible to generate a homozygous humanized mouse strain by intercrossing heterozygotes that carry the human replacement.
Traditionally, this approach has involved small size changes (up to ~10 kb) to replace some or all of the exons and introns of a mouse gene with the corresponding human sequence; the human sequence therefore remains under the control of mouse transcriptional regulatory sequences. Mice in which the genomic region encompassing exons 4-9 of the Trp53 gene was replaced by the orthologous human genomic region have been constructed by this approach and have a correct splicing pattern, producing a chimeric protein in which the p53 core domain is human 12, 13 . However, replacements are now possible in which an entire mouse locus, including non-coding upstream and downstream sequences, is substituted by equivalent human sequence using constructs derived from BACs. In principle, this approach could be extended to encompass a larger region of shared synteny. There are two ways of achieving this aim (described below and shown in FIG. 1b,c) : either directly by using homologous recombination or through a multi-step approach that involves a combination of homologous recombination and SSR.
BAC vector homologous recombination.
Genomic replacements can be achieved by homologous recombination with a hybrid BAC vector (FIG. 1b) . This vector is assembled from mouse and human BAC clones by recombineering technology in E. coli to create a construct with a large region of human sequence and a drug resistance marker inserted between long regions of mouse genomic sequence (>100 kb in total). As a consequence of the length of the mouse sequences that form the homology arms, this targeting vector results in efficient homologous recombination in ESCs 14 . Targeted integration is detected using quantitative PCR to assay for the reduction in copy number of mouse autosomal sequences from two to one. The advantage of this strategy is that it can be directly applied to unmodified ESCs and is essentially a single-step procedure, although a second step to delete the selection marker using SSR is usually desirable.
A high-throughput version of this technique has been developed, termed 'VelociGene' , that allows rapid generation of large numbers of genetically modified mouse lines 14 . So far, most mouse lines made using VelociGene contain null alleles, in that the entire mouse locus is replaced with a reporter cassette that is driven by the endogenous promoter. This high-throughput technology is being used by the US National Institutes of Health (NIH) as part of their Knockout Mouse Project (KOMP).
VelociGene has been successfully used to create a series of humanized knockins to improve xenogeneic transplantation mouse models for studying in vivo human haematopoiesis and immune function. Four different cytokines have been humanized in three separate targeting events. Both thrombopoietin (TPO) and colony stimulating factor 1 (CSF1) were humanized in single targeting events 15, 16 . For both loci, the mouse promoter was left intact, but the coding region and sequence extending to 3 kb downstream of the poly(A) signal was replaced with the human equivalent (changes of 5 kb and 18 kb, respectively). Granulocyte macrophage CSF2 and interleukin 3 (IL3) were humanized in the same targeting event owing to their close proximity (<10 kb) in both the mouse and human genome 17 . The dual targeting construct replaced the mouse loci with the human equivalents (a change of 20 kb): whereas Box 1 | Why humanize mice?
Genetic humanization
Few proteins are 100% conserved between humans and mice 46 , and differences in orthologous sequences can have functional consequences. For example, mouse serum amyloid P (SAP) binds to amyloid fibrils with only ~3% of the avidity of the human protein, although mouse and human SAP sequences are ~70% conserved 47 . Similarly, mutant superoxide dismutase 1 (SOD1) is causative for the human neurodegenerative disease amyotrophic lateral sclerosis. The human and mouse proteins share 83% identity, but a tryptophan residue at codon 32 (W32), which is only found in humans, appears to potentiate SOD1 aggregation and human-specific SOD1-SOD1 interaction, which may contribute to motor neuron death in humans and in mice with mutant human SOD1 transgenes 48 . Similarly, wild-type mice that express mouse CD81 and occludin (OCLN) are non-permissive to hepatitis C virus (HCV) entry 49 . However, animals that express human orthologues of these two proteins are permissive for HCV infection but remain fully immunocompetent. This model greatly eases studies of the immune response to HCV, because humans and chimpanzees were previously the only two species known to be permissive for HCV infection 49 . Humanization also gives insight into gene evolution. The forkhead box P2 (FOXP2) transcription factor is important for human speech and language. When this protein was humanized in mice, it produced abnormal phenotypes in cortico-basal ganglia circuits, suggesting that humanized FOXP2 may have taken on a new function (or functions) in these regions during the evolution of human language and speech 50 . These phenotypes were not found in a mouse Foxp2 knockout, indicating that they arose from the wild-type human protein.
For a small number (<200) of human protein-coding genes, no mouse orthologue has been found 51 , and thus one approach for learning more about the biology of these human genes is to introduce them into mice.
Genomic humanization
Although genetic humanization has given us great biological insight, 'genomic' humanization will be necessary in order to investigate the functional importance of non-coding regions and therefore to model aneuploidy fully, to study disorders in which species-specific splicing patterns have a role or to determine the functions of untranslated sequences. For example, the different effects of disrupting HOTAIR in humans and its orthologue in mice indicate that this long non-coding RNA has a function (or functions) in humans that may not easily be determined from non-genomically humanized mice 52, 53 . Likewise, genomically humanized mice containing a caspase 12 (CASP12) variant responded in a gender-specific manner when infected with Listeria monocytogenes 54 , leading to the identification of an oestrogen receptor element (ERE) in intron 7 that appears to be responsible for oestrogen-modulated expression of the CASP12 variant being studied. Treatment of the male humanized CASP12 mice with 17-β-oestradiol (E2) conferred increased resistance to infection, leading to suggestion of the therapeutic use of E2. The ERE is not found in mouse intron 7, and wild-type male mice do not respond to oestrogen at the Casp12 locus 54 . Without the use of genomically humanized mice, this ERE and potential therapy would not have been discovered.
Thus, the non-coding genome must be taken into account in studying gene function and genomic humanization will be essential to create an optimal set of models of human disease. Figure 1 | Methods of humanized mouse synthesis. There are multiple ways of introducing the human genomic region of interest into the mouse germline. a | Traditionally, this has been achieved by an additive process, where a yeast artificial chromosome (YAC) or a bacterial artificial chromosome (BAC) vector is introduced into a mouse egg or embryonic stem cell (ESC) by pronuclear injection or cell fusion, respectively. Vectors are incorporated at random locations in the mouse genome, and so the endogenous mouse locus is unmodified. b | An alternative to random integration is the specific targeting and replacement of genomic loci. One way of doing this is using homologous recombination. Homologous recombination with a genomic fusion (mouse-human) BAC vector results in the endogenous mouse locus being replaced by equivalent human sequence: the large regions of homology that are provided by the BAC vector provide increased targeting efficiency. c | Another way of targeting and replacing genomic loci is using site-specific recombination (SSR)-based technologies, such as recombinase-mediated cassette exchange (RMCE) and recombinasemediated genomic replacement (RMGR). RMCE and RMGR require prior modification of the mouse genome to introduce heterotypic SSR sites to flank the region of interest. A BAC vector containing the equivalent human genomic region flanked by the same SSR sites then acts as a donor for the swap of genetic material mediated by expression of recombinase. d | A non-integrative approach for creating a humanized mouse is through the introduction of a human artificial chromosome (HAC) into ESCs by microcell-mediated chromosome transfer (MMCT). The HAC vector is synthesized by a topdown or bottom-up approach, in which the genomic region of interest is introduced by homologous recombination or SSR. The HAC is mitotically stable and is maintained as an extra-chromosomal element, leaving the mouse genome unmodified. As in panel a, all of the mice produced from methods shown in panels b, c and d may then be bred to null mice for the relevant locus, thereby generating an entirely humanized mouse for that region of the genome. Recombinase-mediated cassette exchange and recombinase-mediated genomic replacement. The second approach to 'humanization by replacement' is to use SSR to achieve efficient exchange of a chromosomal sequence with a sequence on an incoming plasmid or BAC. This involves a strategy termed recombinase-mediated cassette exchange (RMCE). RMCE is a two-stage process. First, a selection marker cassette that is flanked by heterospecific SSR sites is integrated into the genome by homologous recombination, deleting the region that is to be replaced. Second, another donor vector carrying the human genomic sequence that is flanked by the same SSR sites is introduced in the presence of a recombinase (usually expressed from a co-transfected plasmid), resulting in the human sequence recombining into the genome (FIG. 1c) . RMCE has been applied in various cell lines, including ESCs 19, 20 . The advantage of RMCE is that, after the initial selection marker cassette has been integrated into the desired chromosomal position, the resulting cell line can be used recursively for unlimited rounds of cassette exchange by the inserted heterospecific sites, and the desired events are readily recovered by genetic selection.
In principle, RMCE could be applied to any gene in mouse ESCs. For example, RMCE was used to place a human cDNA for a cardiac sodium channel in exon 2 of the mouse orthologue 21 . For large-scale replacement of a mouse genomic sequence with a human sequence from a BAC clone, an elaboration of the RMCE strategy can be used called recombinase-mediated genomic replacement (RMGR) 22 . In RMGR, heterospecific SSR sites and linked positive and negative selection markers are integrated into ESCs by sequential rounds of homologous recombination to delineate the region for replacement. The human BAC clone is modified by recombineering to insert heterospecific SSR sites at the corresponding human sequences and, following cotransfection with a Cre-recombinaseexpressing plasmid, SSR events at both ends are selected (FIG. 1c) . This method was used to replace the 87 kb genomic region encompassing the α-globin regulatory domain of mice with the equivalent human sequence of 117 kb. An additional round of recombineering of the BAC was used to delete the major regulatory element before its introduction into ESCs and, consequently, to create a mouse model of human α-thalassaemia 22 .
Theoretically, RMGR could encompass replacements of any size up to the size limit of the BAC donor. Recently, Hasegawa and co-workers 23 published a modified version of RMGR in which they flanked the mouse cytochrome P450 Cyp3a gene cluster (a region of 820 kb) with a pair of homospecific loxP sites that allowed deletion of this cluster in an intermediate step. These sites were present in addition to the heterospecific sites that are required to insert human CYP3A4 and CYP3A7 contained within a 100 kb region of the donor BAC. The resulting humanized mouse has been created to study drug interactions.
Engineering human chromosomes
Copy number variation (CNV) is highly polymorphic in the human population, and it is likely that many CNVs give rise to phenotypic effects because of differences in sequence dose between individuals. Genomic CNV can be modelled through chromosome engineering of the mouse genome 24, 25 , but to model the effects of human CNVs that span extensive regions of non-coding sequence, genomically humanized mice carrying different copy numbers of the human sequence will need to be generated.
Humanized mouse models carrying a freely segregating partial or whole human chromosome have been created using microcell-mediated chromosome transfer (MMCT) into mouse ESCs [26] [27] [28] . These transchromosomic ESCs are then used in conventional approaches to establish strains of transchromosomic mice that transmit the human chromosome through the germline (FIG. 1d) . For example, the Tc1 mouse carries a freely segregating human chromosome 21 and models trisomy 21 in humans 26 . Human artificial chromosomes (HACs) offer alternatives as vectors for gene delivery and for creating animal models 29, 30 . HACs are non-integrating vectors that can be engineered to contain desired sequences and then moved by MMCT into mouse ESCs to make transchromosomic mice 31 . HACs are synthesized by two methods, either 'bottomup' (de novo) synthesis or 'top-down' (engineered) synthesis. The bottom-up approach involves introduction of two vectors, BAC or YAC, into cells that are permissive for recombination. One vector contains centromeric alphoid DNA, and the other contains the genomic region of interest. Multiple copies of each vector are randomly assembled with no control on size or composition. The resultant HACs are usually circular and 1-10 Mb in size. The top-down approach involves shortening human chromosomes by inserting telomeric sequences into specific sites by homologous recombination to form mini-chromosomes. Efficiency of recombination is increased if this step is carried out in chicken DT40 cells, which are unusually permissive for homologous recombination. More recently, SSR sites have been introduced into engineered HACs, allowing the introduction of any genomic region flanked by SSR sites that are present in a donor vector (BAC or YAC). The latest generation of engineered HACs have been designed with gene therapy and synthesis of animal models in mind. For example, HACs containing multiple different SSR sites 32 allow the introduction of multiple genes of interest on the same vector, whereas the tetO HAC 33 is conditional and, after it has been introduced, it can be selectively removed from cells (the current generation of HAC vectors are reviewed in REF. 34 ).
The merits of creating transchromosomic mice are that they carry low or single copy number human chromosomes or HACs, they are generally freely segregating and thus do not disrupt endogenous sequences and, presumably, their maximum size is that of a chromosome 34 . A possible disadvantage of this approach may be the instability of the transchromosomes, although this has not been reported to be a problem.
Mouse models for developing therapies
In addition to understanding pathogenic processes, genomically humanized mouse models are likely to be important for developing therapies, particularly gene therapies. In a recent example, a genomically humanized mouse strain was created by knocking a minigene for human factor 9 (F9) into the ubiquitously expressed Rosa26 locus; this minigene included intron 1 and the Y155stop mutation, which is known to cause haemophilia B 35 . This humanized F9 mouse was then used to develop in vivo gene therapy, using zinc finger nucleases plus a promoterless therapeutic gene fragment consisting of wild-type F9 cDNA exons 2-8 preceded by a splice acceptor site. The sitespecific nucleases corrected the mutant F9 gene by inserting the gene fragment into the first intron of F9. It is difficult to imagine how this therapeutic approach for treating haemophilia B could have been validated without the use of such mice.
Existing and new resources
Comparisons between existing strains of mutant mice and humanized genomic models can be highly instructive for understanding species-specific biology 36, 37 . Additive multi-copy transgenics will also continue to be necessary for modelling disorders, such as some late-onset neurodegenerative diseases, in which expression of human sequences needs to attain a threshold level to manifest a phenotype 38 . Furthermore, existing mouse genetic resources can be used to understand the effects of genetic modifiers by breeding humanized loci into different inbred mouse lines 39 or into genetically sensitized mouse strains. Similarly, we may be able to dissect the effects of the environment on human genetic disease by altering the conditions in which genetically identical humanized mouse models are maintained.
Our ability to humanize mice is likely to increase greatly in the near future. New applications might include iterative application of the VelociGene technology along the length of a chromosome to create contiguous regions of humanization. Humanization of multiple loci, either linked or unlinked, could also be achieved in an ESC line by extending RMGR technology. For example, targeting vectors that have already been generated by the International Knockout Mouse Consortium could be adapted to insert heterotypic SSR sites and/or selection markers into the mouse genome, and corresponding human BACs that overlap these loci could be used as donors. Alternatively, BACs could be joined by recombineering into a single mega-BAC to span the desired region. New SSR systems, such as Dre-rox recombination will undoubtedly be useful in implementing this strategy 40 .
Glossary

Conditional mutations
Mutated sequences that are expressed under experimental control. For example, in a conditional knockout, deletion of a crucial exon that is flanked by recombination sites can be induced by expressing a recombinase that is under the control of a tissuespecific promoter.
Gene targeting
A method of exchanging genetic information from a donor vector into a recipient genome by exploiting a DNA repair mechanism that recognizes homology between the donor DNA and the recipient locus. It results in the replacement of the original genomic sequence with the donor sequence.
Genome-wide association studies (GWASs). Whole-genome scans that are designed to test the statistical association between finely spaced polymorphic genetic markers and traits under study. Large numbers of phenotypically well-classified DNA samples are required to have sufficient statistical power to detect such associations.
Inducible mutations
A class of conditional mutation that is expressed by using a ligand-inducible recombinase. Inducible mutations allow recombinase-driven changes to be induced at a particular time point by delivering the ligand into the animal by injection, diet or using viral vectors.
Knock-in mice
Mice carrying a targeted replacement or insertion. This could be generated by an exchange of nucleotide sequence to change the encoded protein sequence or by an insertion to create a tagged protein.
Knockout mice
Mice in which the functional protein-coding capacity of a particular gene has been disrupted. This could be generated by a targeted deletion, gene trap, or targeted conditional knockout. Microcell-mediated chromosome transfer (MMCT). A method for transferring entire chromosomes or chromosome fragments from a donor cell line into a recipient cell line.
Knockout Mouse Project
Minigene
A gene construct that contains fewer exons and introns than its original full gene counterpart. Minigenes have been used to investigate regulatory sequences but may also be used because of their more convenient size.
Pronuclear injection
A process by which DNA is added to the genome, generally to create transgenic mice. Linearized DNA is injected into one of the two pronuclei of the fertilized egg, where it is stably incorporated into the genome. The eggs are then developed to term in a pseudopregnant female mouse.
Recombineering
Derived from 'recombination-mediated genetic engineering', this process uses recombination functions encoded by λ-phages to mediate in vivo recombination using short stretches of homologous sequence (30-50 nucleotides long) that can be readily appended to the termini of any desired DNA fragment.
Transchromosomic mouse strains
A mouse strain into which either an entire chromosome or a chromosome fragment from another species has been transferred. This chromosome or chromosome fragment may be freely segregating or inserted into an existing mouse chromosome.
Xenogeneic transplantation
The transplantation of tissues or cells derived from one species into another. For example, the introduction of human stem cells into an immune-deficient mouse strain.
If large-scale changes are required, it should also be possible to use chromosome engineering to apply RMGR on a megabase scale. In this scenario, HACs that are maintained in DT40 cells could first be modified by homologous recombination to insert SSR sites and selection markers at the desired end points of the prospective replacement interval. Subsequently, the HACs could be transferred by MMCT into mouse ESCs that have previously been modified by targeted insertion of SSR sites and selection markers at the equivalent chromosomal positions. Expression of recombinase could then be induced to mediate the replacement event between the HAC and the mouse chromosome. This is an exciting prospect for modelling large CNVs and aneuploidies.
Current experience with transchromosomic mice is limited. Recognized issues include difficulty in obtaining germline transmission of the freely segregating human chromosome and its subsequent mosaicism in the animal 26, 41 . One way around these problems may be to engineer the human chromosome, such that it is translocated onto a mouse chromosome, although this inevitably means deletion of some human and mouse sequences at the translocation breakpoints.
Conclusion
As the technologies that are necessary for producing genomically humanized models develop further, it will become possible to introduce greater amounts of human genetic material into mice and other species. This prospect has promoted discussion about the ethical implications of such humanization: for example, in a report from the UK Academy of Medical Sciences, published in July 2011, which is freely available online 42 .
A key question about genomically humanized mice concerns the extent to which the human DNA sequence is correctly and efficiently read by the mouse transcriptional machinery. Little information is available, partly because there are few genomically humanized models. It is reassuring that in the α-globin humanized mouse model, the human genes are expressed in an appropriate developmental stage-and cell-type-specific manner 22 . However, in humanized heterozygotes, human α-globin RNA is expressed at 40% of the level of endogenous mouse α-globin, possibly because the relevant mouse transcription factors bind cognate human sequences with suboptimal efficiency or stability. Nevertheless, the humanized α-globin locus accurately recapitulates many of the important features of the human α-globin gene chromatin state 43, 44 . Consistent with this observation, a recent study showed that when a human chromosome is placed in a mouse environment, the human DNA sequence directs a human rather than a mouse pattern of chromatin modifications 45 . We have learned a substantial amount from genetically humanized mice already. The tools that are now available and those that are yet to come will allow more accurate manipulation of the mouse genome with engineered human genomic material. This holds great promise for the improved understanding of disease and for the development of effective therapies and more accurate models of drug metabolism, as well as for enhancing our understanding of mammalian and human genome function.
